MILTUXIMAB Trademark

Trademark Overview

On Wednesday, September 13, 2017, a trademark application was filed for MILTUXIMAB with the United States Patent and Trademark Office. The USPTO has given the MILTUXIMAB trademark a serial number of 79219018. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, December 6, 2024. This trademark is owned by Minomic International Ltd.. The MILTUXIMAB trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for the diagnosis, treatment, or prevention of cancer, oncological disorders, auto-immune diseases, and inflammation diseases

General Information

Serial Number79219018
Word MarkMILTUXIMAB
Filing DateWednesday, September 13, 2017
Status709 - CANCELLED - SECTION 71
Status DateFriday, December 6, 2024
Registration Number5472258
Registration DateTuesday, May 22, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 6, 2018

Trademark Statements

Goods and Servicespharmaceutical preparations for the diagnosis, treatment, or prevention of cancer, oncological disorders, auto-immune diseases, and inflammation diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, December 6, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMinomic International Ltd.
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressAU
Party NameMinomic International Ltd.
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressAU
Party NameMinomic International Ltd.
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressAU

Trademark Events

Event DateEvent Description
Thursday, October 19, 2017SN ASSIGNED FOR SECT 66A APPL FROM IB
Wednesday, October 25, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 31, 2017APPLICATION FILING RECEIPT MAILED
Saturday, December 16, 2017ASSIGNED TO EXAMINER
Wednesday, December 20, 2017NON-FINAL ACTION WRITTEN
Thursday, December 21, 2017NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, January 10, 2018REFUSAL PROCESSED BY MPU
Wednesday, January 10, 2018NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, January 23, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, January 23, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 23, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 24, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 25, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, January 27, 2018REFUSAL PROCESSED BY IB
Wednesday, February 14, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 6, 2018PUBLISHED FOR OPPOSITION
Tuesday, March 6, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 22, 2018REGISTERED-PRINCIPAL REGISTER
Wednesday, August 22, 2018FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, September 5, 2018FINAL DISPOSITION PROCESSED
Wednesday, September 5, 2018FINAL DISPOSITION NOTICE SENT TO IB
Saturday, September 29, 2018FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, October 1, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, October 1, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, October 1, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, October 1, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, October 1, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, October 30, 2020NEW REPRESENTATIVE AT IB RECEIVED
Friday, December 6, 2024CANCELLED SECTION 71

Related Keywords

miltuximab diseases disorders auto immune oncological inflammation cancer preparations diagnosis treatment